Life sciences commited $15 billion in new construction in the US in 2014, up 25% over 2013
Survey of construction projects and facility upgrads finds 739 projects initiated
Industrial Info Resources (Sugar Land, TX), which compiles construction activity nationally, primarily for the benefit of the engineering-construction companies bidding for the business, toted up $15 billion worth of projects in 2014. The count includes projects that have reached the construction stage (and not preliminary engineering and design), in pharma, biotech and medical devices. The 2013 total that IIR reported was $12 billion.
“The 2014 projects are a good reflection of the industry as a whole and where its capital dollars are going: manufacturing, research and distribution,” says Annette Kreuger, IIR analyst. Even "Big Pharma" has rejoined the action, as illustrated by Eli Lilly's launch of a $140-million expansion of insulin cartridge production at its Indianapolis campus. This is the latest in a series of expansions at the site.”
Other notable projects IIR cites are a Michigan State University's launch of the $730-million Rare Isotope Facility at Michigan State University and a $140-million kidney-dialysis project by Fresenius Medical Care North America in Knoxville, TN. Capital spending was highest in the Great Lakes region, at $2.6 billion, the Southeast, at $2.2 billion, and New England, at $2 billion.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
